Has molecular imaging delivered to drug development?

Area of Science:

• Pharmaceutical Sciences
• Medical Imaging
• Drug Development

Background:

• Early-stage pharmaceutical research requires rigorous evaluation of drug candidates.
• Understanding drug exposure, target binding, and pharmacological response is crucial for efficient resource allocation.
• Molecular imaging presents a promising tool for quantitative characterization in early clinical studies.

Purpose of the Study:

• To explore the potential of molecular imaging in early clinical drug development.
• To identify the benefits and challenges of integrating molecular imaging into pharmaceutical research.
• To propose strategies for broadening the use and impact of molecular imaging.

Main Methods:

• Review of current drug development needs and molecular imaging applications.
• Analysis of impediments to the wider adoption of molecular imaging in clinical studies.
• Consideration of proposed models for enhanced integration and impact.

Main Results:

• Molecular imaging provides non-invasive, whole-body assessment, particularly valuable for neuroscience drug development.
• Current adoption is limited despite the technology's potential to enable earlier, data-driven decisions.
• Several impediments hinder broader integration into standard clinical studies.

Conclusions:

• Molecular imaging is a powerful platform for characterizing drug candidates early in development.
• Overcoming current challenges is essential for realizing the full potential of molecular imaging in pharmaceutical R&D.
• Broader implementation can lead to more efficient and impactful drug development.